OPTN RSI Chart
Last 7 days
3.3%
Last 30 days
23.5%
Last 90 days
-8.0%
Trailing 12 Months
-29.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 74.0M | 0 | 0 | 0 |
2023 | 73.4M | 72.2M | 72.0M | 71.0M |
2022 | 77.5M | 79.7M | 77.9M | 76.3M |
2021 | 54.0M | 62.1M | 68.5M | 74.7M |
2020 | 40.3M | 35.5M | 38.6M | 49.1M |
2019 | 10.7M | 16.1M | 29.2M | 39.9M |
2018 | 31.3M | 23.2M | 15.2M | 7.1M |
2017 | 0 | 0 | 0 | 39.4M |
2016 | 0 | 0 | 0 | 47.5M |
2015 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 18, 2024 | krick anthony j | sold | -4,408 | 1.88 | -2,345 | chief accounting officer |
Mar 18, 2024 | marino michael f iii | sold | -28,310 | 1.88 | -15,059 | chief legal officer & corp sec |
Mar 18, 2024 | mahmoud ramy a | sold | -36,092 | 1.88 | -19,198 | chief executive officer |
Mar 15, 2024 | mahmoud ramy a | acquired | - | - | 6,114 | chief executive officer |
Mar 15, 2024 | marino michael f iii | acquired | - | - | 3,816 | chief legal officer & corp sec |
Feb 28, 2024 | mahmoud ramy a | acquired | - | - | 795,975 | chief executive officer |
Feb 28, 2024 | krick anthony j | acquired | - | - | 112,500 | chief accounting officer |
Feb 28, 2024 | marino michael f iii | acquired | - | - | 280,000 | chief legal officer & corp sec |
Feb 28, 2024 | spence paul jr. | acquired | - | - | 252,675 | chief commercial officer |
Jan 31, 2024 | mahmoud ramy a | sold | -69,266 | 1.31 | -52,875 | chief executive officer |
Which funds bought or sold OPTN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Garner Asset Management Corp | sold off | -100 | -324 | - | -% |
May 16, 2024 | Arete Wealth Advisors, LLC | sold off | -100 | -12,900 | - | -% |
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -78,891 | - | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.92 | -4,779 | 10,702 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -38.23 | -3,433 | 7,979 | -% |
May 15, 2024 | Nantahala Capital Management, LLC | reduced | -60.69 | -4,506,580 | 3,612,470 | 0.21% |
May 15, 2024 | PRELUDE CAPITAL MANAGEMENT, LLC | added | 33.33 | 177,300 | 525,600 | 0.03% |
May 15, 2024 | Mariner, LLC | reduced | -62.9 | -25,573 | 18,508 | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 449,115 | 449,115 | -% |
May 15, 2024 | GREAT POINT PARTNERS LLC | reduced | -0.61 | 1,424,500 | 12,828,000 | 2.00% |
Unveiling Optinose Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Optinose Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Optinose Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q3 | 2019Q2 |
Revenue | -25.1% | 14,880,000 | 19,864,500 | 19,823,000 | 19,454,000 | 11,846,000 | 20,856,000 | 20,078,000 | 20,582,000 | 14,760,000 | 22,509,000 | 21,826,000 | 18,357,000 | 11,960,000 | 16,347,000 | 15,436,000 | 10,272,000 | 7,062,000 | 5,819,000 | 12,397,000 | 15,000,000 | 6,677,000 |
Costs and Expenses | 2.6% | 22,955,000 | 22,377,500 | 21,517,000 | 23,626,000 | 26,214,000 | 29,212,000 | 30,878,000 | 35,927,000 | 36,155,000 | 34,175,000 | 34,866,000 | 37,912,000 | 34,149,000 | - | - | - | - | - | - | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 34,866,000 | 37,912,000 | 34,149,000 | - | 33,320,000 | 32,871,000 | 33,348,000 | - | 32,206,000 | - | 32,384,000 |
S&GA Expenses | 8.2% | 20,518,000 | 18,960,500 | 18,011,000 | 20,104,000 | 22,723,000 | 23,310,000 | 25,486,000 | 29,514,000 | 29,339,000 | 26,340,000 | 25,801,000 | 27,308,000 | 27,184,000 | 28,106,000 | 24,575,000 | 25,697,000 | 27,060,000 | 26,545,000 | 25,270,000 | - | 26,000,000 |
R&D Expenses | -6.2% | 1,206,000 | 1,286,000 | 1,281,000 | 951,000 | 1,785,000 | 2,921,000 | 3,267,000 | 4,270,000 | 4,802,000 | 5,260,000 | 6,654,000 | 8,179,000 | 5,225,000 | 6,448,000 | 6,524,000 | 5,474,000 | 4,932,000 | 5,379,000 | 5,547,000 | - | 5,295,000 |
EBITDA Margin | - | - | - | - | - | - | - | - | -0.82 | -0.85 | -0.88 | - | - | -1.56 | -1.74 | -2.21 | -2.40 | -2.65 | -2.87 | -3.61 | -5.98 | -5.98 |
Interest Expenses | -2.4% | 4,970,000 | 5,092,000 | 4,940,000 | 4,824,000 | 4,672,000 | 4,477,500 | 4,207,000 | 4,086,000 | 4,073,000 | 4,013,500 | 4,072,000 | 4,012,000 | 3,876,000 | 3,502,000 | 3,350,000 | 3,293,000 | 2,863,000 | 2,474,500 | 2,372,000 | - | 2,389,000 |
EBT Margin | - | - | - | - | - | - | - | - | -1.03 | -1.06 | -1.10 | - | - | -1.85 | -2.03 | -2.51 | -2.70 | -2.96 | -3.18 | -4.01 | -6.63 | -6.63 |
Net Income | -41.1% | -14,067,000 | -9,967,500 | -9,294,000 | 2,626,000 | -18,847,000 | -15,149,000 | -14,954,000 | -19,397,000 | -25,333,000 | -15,624,000 | -17,117,000 | -23,502,000 | -26,053,000 | -23,863,000 | -21,214,000 | -25,852,000 | -28,856,000 | -24,995,000 | -28,808,000 | - | -27,376,000 |
Net Income Margin | 17.0% | -0.41 | -0.50 | -0.56 | -0.64 | -0.93 | -0.98 | -0.97 | -0.97 | -1.05 | -1.10 | -1.32 | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -422.5% | -22,047,000 | 6,836,000 | -4,601,000 | -12,617,000 | -10,478,000 | -17,683,000 | -17,508,000 | -13,140,000 | -19,383,000 | -16,740,000 | -9,729,000 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -22.3% | 84.00 | 108 | 101 | 106 | 115 | 144 | 105 | 123 | 134 | 166 | 132 | 140 | 158 | 189 | 181 | 153 | 174 | 173 | 149 | 167 | 193 |
Current Assets | -23.0% | 81.00 | 105 | 99.00 | 104 | 112 | 140 | 101 | 118 | 128 | 160 | 125 | 133 | 150 | 181 | 172 | 149 | 170 | 168 | 144 | 161 | 187 |
Cash Equivalents | -29.9% | 52.00 | 74.00 | 67.00 | 71.00 | 84.00 | 94.00 | 61.00 | 78.00 | 91.00 | 111 | 84.00 | 94.00 | 116 | 144 | 143 | 125 | 149 | 147 | 126 | 144 | 171 |
Inventory | 28.1% | 10.00 | 8.00 | 8.00 | 8.00 | 8.00 | 9.00 | 10.00 | 11.00 | 11.00 | 12.00 | 13.00 | 13.00 | 13.00 | 9.00 | 9.00 | 6.00 | 6.00 | 3.00 | 4.00 | 4.00 | 6.00 |
Net PPE | -7.5% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 |
Liabilities | -5.9% | 183 | 194 | 179 | 176 | 189 | 201 | 179 | 184 | 179 | 188 | 183 | 177 | 175 | 182 | 153 | 140 | 139 | 111 | 105 | 98.00 | 101 |
Current Liabilities | -81.5% | 33.00 | 177 | 164 | 164 | 166 | 179 | 178 | 55.00 | 50.00 | 59.00 | 54.00 | 47.00 | 45.00 | 52.00 | 43.00 | 35.00 | 34.00 | 36.00 | 30.00 | 24.00 | 27.00 |
Long Term Debt | - | 131 | - | - | - | - | - | - | 127 | 127 | 126 | 127 | 126 | 126 | 125 | 105 | 105 | 105 | 75.00 | 74.00 | 73.00 | 73.00 |
LT Debt, Current | -100.0% | - | 130 | 130 | 129 | 129 | 129 | 128 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | 126 | - | - | - | 125 | - | - | - | 75.00 | - | - | - |
Shareholder's Equity | -14.6% | -99.22 | -86.61 | - | - | -73.79 | -56.62 | - | - | - | - | - | - | - | 7.00 | 28.00 | 13.00 | 35.00 | 62.00 | 45.00 | 68.00 | 92.00 |
Retained Earnings | -2.0% | -734 | -720 | -710 | -701 | -703 | -684 | -669 | -654 | -635 | -610 | -594 | -577 | -553 | -527 | -503 | -482 | -456 | -427 | -402 | -374 | -346 |
Additional Paid-In Capital | 0.2% | 635 | 634 | 633 | 631 | 630 | 628 | 596 | 594 | 591 | 588 | 543 | 540 | 537 | 535 | 532 | 495 | 492 | 490 | 448 | 443 | 439 |
Shares Outstanding | 0.6% | 113 | 112 | 112 | 112 | 112 | 111 | 83.00 | 83.00 | 82.00 | 82.00 | 53.00 | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 119 | - | - | - | 202 | - | - | - | 95.00 | - | - | - | 176 | - | - | - | 174 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -418.8% | -22,025 | 6,909 | -4,425 | -12,538 | -10,478 | -17,680 | -17,498 | -13,138 | -19,335 | -16,716 | -9,701 | -22,494 | -28,024 | -19,156 | -15,532 | -23,550 | -27,968 | -18,106 | -15,127 | -27,888 | -29,694 |
Share Based Compensation | 48.7% | 1,456 | 979 | 1,195 | 1,501 | 1,523 | 1,486 | 1,947 | 3,447 | 1,997 | 1,976 | 2,684 | 2,733 | 2,610 | 2,492 | 2,625 | 2,772 | 2,460 | 2,308 | 2,435 | 2,695 | 2,422 |
Cashflow From Investing | 69.9% | -22.00 | -73.00 | -176 | -79.00 | - | -3.00 | -10.00 | -2.00 | -48.00 | -24.00 | -28.00 | 81.00 | -91.00 | -86.00 | -151 | -239 | -70.00 | -72.00 | -62.00 | -255 | -168 |
Cashflow From Financing | 75.0% | 7.00 | 4.00 | 135 | -1.00 | 162 | 50,787 | 373 | 27.00 | 249 | 43,009 | 35.00 | 347 | -71.00 | 20,308 | 33,552 | 572 | 29,378 | 39,831 | -3,283 | 793 | 188 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Total revenues | $ 14,880 | $ 11,846 |
Costs and expenses: | ||
Cost of product sales | 1,231 | 1,706 |
Research and development | 1,206 | 1,785 |
Selling, general and administrative | 20,518 | 22,723 |
Total costs and expenses | 22,955 | 26,214 |
Loss from operations | (8,075) | (14,368) |
Other (income) expense: | ||
Unrealized loss on fair value of warrants | 1,300 | 510 |
Interest income | (296) | (705) |
Interest expense | 4,970 | 4,672 |
Foreign currency loss | 18 | 2 |
Net loss | $ (14,067) | $ (18,847) |
Net loss per share of common stock, basic (in dollars per share) | $ (0.12) | $ (0.17) |
Net loss per share of common stock, diluted (in dollars per share) | $ (0.12) | $ (0.17) |
Weighted average common shares outstanding, basic (in shares) | 112,594,852 | 111,774,425 |
Weighted average common shares outstanding, diluted (in shares) | 112,594,852 | 111,774,425 |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | Net product revenues | Net product revenues |
Net product revenues | ||
Total revenues | $ 14,880 | $ 11,846 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 51,644 | $ 73,684 |
Accounts receivable, net | 14,227 | 19,926 |
Inventory | 10,315 | 8,052 |
Prepaid expenses and other current assets | 4,936 | 3,671 |
Total current assets | 81,122 | 105,333 |
Property and equipment, net | 754 | 815 |
Other assets | 1,831 | 1,581 |
Total assets | 83,707 | 107,729 |
Current liabilities: | ||
Accounts payable | 1,912 | 3,886 |
Accrued expenses and other current liabilities | 30,793 | 42,411 |
Short term debt, net | 0 | 130,227 |
Total current liabilities | 32,705 | 176,524 |
Long term debt, net | 130,653 | 0 |
Warrant liability | 18,500 | 17,200 |
Other liabilities | 1,065 | 611 |
Total liabilities | 182,923 | 194,335 |
Stockholders' deficit | ||
Preferred stock, no par value; 5,000,000 shares authorized; no shares issued in 2024 or 2023 | 0 | 0 |
Common stock, $0.001 par value; 350,000,000 shares authorized; 113,038,726 and 112,399,495 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively. | 113 | 112 |
Additional paid-in capital | 635,198 | 633,742 |
Accumulated deficit | (734,443) | (720,376) |
Accumulated other comprehensive loss | (84) | (84) |
Total stockholders' deficit | (99,216) | (86,606) |
Total liabilities and stockholders' deficit | $ 83,707 | $ 107,729 |
 | Dr. Ramy A. Mahmoud M.D., M.P.H. |
---|---|
 | optinose.com |
 | Pharmaceuticals |
 | 141 |